

Influenza Vaccine Manufacturers' Panel Discussion: Setting the Stage

Litjen (L.J) Tan
Chief Strategy Officer, IAC
Co-Chair, NAIIS

1


Setting the Stage

- Things to celebrate (and sustain) from previous flu season
 - Increased in doses administered, by manufacturers' data potentially 17% increase
 - Improvements resulted from concerted CDC messaging, and unified common messages and voices amplified through the Summit and partners
- Things that remain challenging
 - Dramatic fall off in influenza immunizations past November, acknowledging the difficulty of continuing to emphasize flu in the absence of disease and in the midst of a pandemic (see graphic)
 - Lots of vulnerable and underserved populations continued to be under-immunized
 - Vaccine supply has been stable for many years. How do we work together to ensure that we use all doses to protect as many people as possible?



2

2



3

Setting the Stage

- Things to celebrate (and sustain) from previous flu season
 - Increased in doses administered, by manufacturers’ data potentially 17% increase
 - Improvements resulted from concerted CDC messaging, and unified common messages and voices amplified through the Summit and partners
- Things that remain challenging
 - Dramatic fall off in influenza immunizations past November, acknowledging the difficulty of continuing to emphasize flu in the absence of disease and in the midst of a pandemic
 - Lots of vulnerable and underserved populations continued to be under-immunized
 - Vaccine supply has been stable for many years. How do we work together to ensure that we use all doses to protect as many people as possible?

4

Estimated Supply for the 2021-2022 Season

- Influenza vaccine supply has not been a challenge for many years.
- Manufacturers estimate that there will be a combined total of >190 million doses available this 2021-2022 influenza season.
 - Compared with ~170 million doses administered last season (the most ever used)

5

